ArticleCell reports. Medicine2023
The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice.
Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 39 citations in OpenAlex.
- Impact of an aerosolized or intramuscular adenovirus type 5-vectored COVID-19 vaccine on Fc-mediated immune effector functions in a hybrid immunity population.Frontiers in immunology · 2025Trial
- Article
- Fc-engineered antibodies enhance protection against SARS-CoV-2 lung infection and inflammation.mBio · 2026Article
- A triple combination strategy for nasopharyngeal carcinoma: Aptamer-guided liposomal chemotherapy, engineered NK cells, and Fc-enhanced PD-L1 antibody therapy.Acta pharmaceutica Sinica. B · 2026Article
- Fc Functions and Anti-HIV Neutralizing Antibodies: A Perspective.Current HIV research · 2026Article
- Article
- Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants.Journal of virology · 2025Article
- Reduced Fc-mediated antibody responses after COVID-19 mRNA vaccination in a cohort of people living with HIV-1.Scientific reports · 2025Observational
- Decreased Fc fucosylation aligns with enhanced RSV-specific antibody functionality in adults compared to young children.Communications medicine · 2025Article
- Development of broadly neutralizing antibodies against Omicron variants from existing neutralizing antibodies in clinical trials.Virology journal · 2025Article
- Diversity of immunization strongly impacts SARS-CoV-2 antibody function surrogates.NPJ vaccines · 2025Article
- BNT162b2 COVID-19 vaccination elicits the expansion of CD16The Journal of allergy and clinical immunology · 2025Article
- Impact of Vaccine-Elicited Anti-Spike IgG4 Antibodies on Fc-Effector Functions Against SARS-CoV-2.Viruses · 2025Article
- Longitudinal humoral immunity against SARS-CoV-2 Spike following infection in individuals from Cameroon.Virology · 2025Article
- A humanised ACE2, TMPRSS2, and FCGRT mouse model reveals the protective efficacy of anti-receptor binding domain antibodies elicited by SARS-CoV-2 hybrid immunity.EBioMedicine · 2025Article
- Viral glycoprotein-mediated entry and antibody-mediated immunity in HIV-1 and SARS-CoV-2 infection.Frontiers in immunology · 2025Review
- The KT Jeang retrovirology prize 2024: Walther Mothes.Retrovirology · 2024Article
- Sequence Matters: Primary COVID-19 Vaccination after Infection Elicits Similar Anti-spike Antibody Levels, but Stronger Antibody Dependent Cell-mediated Cytotoxicity than Breakthrough Infection.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Repeated COVID-19 mRNA vaccination results in IgG4 class switching and decreased NK cell activation by S1-specific antibodies in older adults.Immunity & ageing : I & A · 2024Article
- Beta Spike-Presenting SARS-CoV-2 Virus-like Particle Vaccine Confers Broad Protection against Other VOCs in Mice.Vaccines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
Abstract
COVID-19 convalescent plasmas (CCPs) are chosen for plasma therapy based on neutralizing titers and anti-Spike immunoglobulin levels. However, CCP characteristics that promote SARS-CoV-2 control are complex and incompletely defined. Using an in vivo imaging approach, we demonstrate that CCPs with low neutralizing (ID
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.